Navigation Links
GENFIT Selected by Windhover for the 2011 'Top Biopharma Projects To Watch'
Date:10/25/2010

LILLE, France and CAMBRIDGE, Mass., Oct. 25 /PRNewswire/ -- GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announced that it has been selected by Windhover as one of the "Top Biopharma Projects To Watch" in 2011 in the cardiovascular/metabolic category. This announcement is part of the conference event organized by Elsevier Business Intelligence and Windhover Conferences taking place in Boston from November 2-4, 2010, where GENFIT will be presenting its latest scientific achievements.

"This year's list is handpicked in the six hottest therapeutic areas," said David Cassak, vice president, content, for Elsevier Business Intelligence's publications. "Many of our past winners have gone on to do big deals, and we expect the same from this year's companies."

The Windhover conference annually elects 10 biopharmaceutical companies with high-value assets for partnership in six specific therapeutic areas: cardiovascular/metabolic, oncology, neuroscience, infectious diseases, inflammatory/autoimmune and a category including ophthalmology, orphan diseases, and women's health. 

Dr. Dean W. Hum, chief scientific officer of GENFIT, added,"Being a well recognized company in the U.S. in our specific therapeutic area is a great honor for us. We will present our most advanced drug candidate in the field of diabetes, GFT505, and our specific and innovative approach to the prevention and treatment of cardiometabolic diseases. This will be illustrated by the presentation of other internal research programs, in particular those dedicated to the discovery of early biomarkers and those dealing with the connection between circadian cycle dysregulation and metabolic diseases."

About Windhover:Windhover Information Inc, an Elsevier company, has provided analysis of the healthcare industry to decision-makers at all levels since the founding of its flagship publication, IN VIVO: The Business & Medicine Report, in 1983. Windhover provides its information and analysis in many formats, including print, electronic databases, international conferences and webinars. For more on the company's products and services, please see www.windhover.com.

About GENFIT:GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases…). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies (SANOFI-AVENTIS, SERVIER, ...), to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase II.  

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 100 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.comContacts:GENFITJean-Francois Mouney – CEO & Chairman of the Management Board+33 (0)3 2016 4000Russo PartnersMartina Schwarzkopf, Ph.D.+1 212 845-4292 / +1 347 591 8785 - martina.schwarzkopf@russopartnersllc.comMilestones – Press RelationsBruno Arabian+33 (0)1 75 44 87 40 / +33 (0)6 87 88 47 26 – barabian@milestones.fr
'/>"/>

SOURCE GENFIT
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX
2. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
3. GeoVax Labs, Inc. Selected by Georgia Bio as 2008 Deal of the Year Award Winner in Life Sciences Industry
4. Caliper Life Sciences Optical Imaging Technology Selected to Aid Tuberculosis Research Efforts by the Texas A&M Health Science Center
5. Cepheid GeneXpert(R) System and Xpert(TM) MRSA Selected for up to 11 Victoria, Australia Hospitals in Rollout of Start Clean Strategy
6. XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention
7. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation
8. Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program
9. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
10. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
11. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)...   Casetabs , the pioneer surgery coordination application, ... the iPhone. With this new release, Casetabs is further ... physician offices, ambulatory surgery centers (ASCs) and hospitals. The ... even faster, more reliable access to case information. ... connect care teams so that surgeries can be coordinated ...
(Date:3/23/2017)... FRANCISCO , March 23, 2017 ... a value of USD 25.7 billion by 2025, according to ... are expected to grow at a faster rate due to ... rising awareness about various types of esthetic procedures used for ... these disorders. Hence, they are considered as the highest revenue ...
(Date:3/23/2017)... NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), ... of the Annual report for 2016 is now available on ... ... Pharmaceutical AB is a leader in mitochondrial medicine. The company ... preserve mitochondrial integrity and function in areas of unmet medical ...
Breaking Medicine Technology:
(Date:3/23/2017)... D.C. (PRWEB) , ... March 23, 2017 , ... ... (LEAD Coalition) stands with all Americans facing life-altering and fatal diseases in opposition ... budget makes shortsighted decisions that would eviscerate care, services, and hope for the ...
(Date:3/23/2017)... ... , ... The Boulevard is honored to host Shriners and Masons Children’s Day ... in the Main West Entrance of The Boulevard (in front of JCPenney). , ... and each child with a parent or guardian will be photographed for free and ...
(Date:3/23/2017)... ... 23, 2017 , ... “Wounded Woman Be Ye Healed-Passing On A Legacy”: a ... Legacy” is the creation of published author, Desiree M Webb, a registered nurse, minister ... has been happily married to her husband, Paul, for over twenty-nine years. Desiree ...
(Date:3/23/2017)... ... March 23, 2017 , ... “The Trainer”: an electrifying ... author, Scotty, a fiction writer with an active imagination and an enthusiasm for action ... follows the tale of Wild Bill Hart, who sat looking at the thirty-three notches ...
(Date:3/22/2017)... ... March 22, 2017 , ... Cosmetic Town, ... first issue of its companion print magazine. The new magazine, scheduled for release ... to information provided by board-certified doctors from across the country. , According to ...
Breaking Medicine News(10 mins):